Provided by Tiger Fintech (Singapore) Pte. Ltd.

Regeneron Pharmaceuticals

521.84
+3.240.62%
Post-market: 521.840.00000.00%19:59 EDT
Volume:873.33K
Turnover:455.34M
Market Cap:56.36B
PE:13.24
High:525.22
Open:517.23
Low:512.97
Close:518.60
Loading ...

BUZZ - S&P 500 top and bottom performing stocks at about 03:30 p.m. EDT

Reuters
·
30 Apr

Regeneron Pharma Margins Tighten As Competition Grows, Stock Slides

Benzinga
·
30 Apr

BUZZ - Nasdaq top and bottom performing stocks at about 02:45 p.m. EDT on 2025-04-29

Reuters
·
30 Apr

Why Regeneron (REGN) Stock Is Falling Today

StockStory
·
30 Apr

Regeneron Sinks As Sales Of Key Eye Medication Tumble -- Market Talk

Dow Jones
·
30 Apr

Regeneron Stock Falls on Q1 Earnings and Sales Miss, Eylea Sales Down

Zacks
·
30 Apr

Oppenheimer Adjusts Price Target on Regeneron Pharmaceuticals to $900 From $925

MT Newswires Live
·
29 Apr

Analysts Conflicted on These Healthcare Names: Galmed Pharmaceuticals (GLMD) and Regeneron (REGN)

TIPRANKS
·
29 Apr

Regeneron's Eylea Setback Drags Stock as Investor Frustrations Mount -- Market Talk

Dow Jones
·
29 Apr

Regeneron Stock Plummets After Earnings Miss -- Barrons.com

Dow Jones
·
29 Apr

Regeneron Pharma's First-Quarter Results Miss on Lower Eylea Demand

Reuters
·
29 Apr

Regeneron Pharmaceuticals Shares Down 10.7% After Quarterly Results Miss

THOMSON REUTERS
·
29 Apr

Regeneron Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
29 Apr

Regeneron (REGN) Reports Q1 Earnings: What Key Metrics Have to Say

Zacks
·
29 Apr

Regeneron Exec Says Potential Impact From Sector-Specific Tariffs Is Not Quantifiable at This Time -Conf Call

THOMSON REUTERS
·
29 Apr

Regeneron (REGN) Lags Q1 Earnings and Revenue Estimates

Zacks
·
29 Apr

BUZZ-Regeneron Pharma falls after quarterly results miss

Reuters
·
29 Apr

Regeneron Shares Down 6.9% Premarket After Q1 Results Miss Estimates

THOMSON REUTERS
·
29 Apr

Regeneron 1Q Profit Rises, Revenue Falls; FY25 CapEx Target Trimmed

Dow Jones
·
29 Apr

Regeneron Pharmaceuticals Q1 2025 Earnings: GAAP EPS of $7.27 Misses Estimate, Revenue Falls Short at $3.0 Billion

GuruFocus
·
29 Apr